EP0285284B1 - N-phenethylaminoalkyl-benzamide anti-arrhythmia agents - Google Patents
N-phenethylaminoalkyl-benzamide anti-arrhythmia agents Download PDFInfo
- Publication number
- EP0285284B1 EP0285284B1 EP88302270A EP88302270A EP0285284B1 EP 0285284 B1 EP0285284 B1 EP 0285284B1 EP 88302270 A EP88302270 A EP 88302270A EP 88302270 A EP88302270 A EP 88302270A EP 0285284 B1 EP0285284 B1 EP 0285284B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- compound
- mmole
- pharmaceutically acceptable
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 ***c1ccc(*)cc1 Chemical compound ***c1ccc(*)cc1 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
Definitions
- This invention relates to certain N-phenethylaminoalkyl-benzamide derivatives which are anti-arrhythmia agents useful for the treatment of cardiac conditions.
- the compounds of the invention prolong the duration of the action potential in cardiac muscle and conducting tissue, and thereby increase refractoriness to premature stimuli.
- they are Class III anti-arrhythmic agents according to the classification of Vaughan Williams (Anti-Arrhythmic Action, E. M. Vaughan Williams, Academic Press, 1980). They are effective in atria, ventricles and conducting tissue both in vitro and in vivo and are therefore useful for the prevention and treatment of a wide variety of ventricular and supraventricular arrhythmias including atrial and ventricular fibrillation. Because they do not alter the speed at which impulses are conducted, they have less propensity than current drugs (mostly Class I) to precipitate or aggravate arrhythmias, and they also produce less neurological side effects. Some of the compounds also have positive inotropic activity and therefore are particularly beneficial in patients with impaired cardiac pump function.
- the pharmaceutically acceptable salts of the compounds of the formula (I) include acid addition salts formed from acids which form non-toxic salts such as the hydrochloride, hydrobromide, hydroiodide, sulphate or bisulphate, phosphate or hydrogen phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, benzoate, methanesulphonate, benzenesulphonate and p-toluenesulphonate salts.
- Some of the compounds may also form metal salts, particularly alkaline earth and alkali metal salts. Examples include the sodium and potassium salts.
- R 1 and R 5 are preferably both CH 3 , R 2 is preferably CH 3 or CH 2 CH 3 , R 3 is preferably H, R 4 is preferably H or OCH 3 and n is preferably 2.
- the invention provides the compound of formula (I) wherein R 1 is CH 3 , R 2 is CH 3 , R 3 is H, R 4 is methoxy attached at the 2-position of the phenyl ring and R 5 is CH 3 , the group -NHS0 2 R 5 being attached at the 4-position of the phenyl ring, and n is 2.
- the invention also provides novel compounds of the following formula : wherein R 2 , R 3 , R 4 and n are as previously defined and R 6 and R 7 are each NH 2 or N0 2 , or R 6 is (C 1 -C 4 alkyl)S0 2 NH and R 7 is NH 2 or N0 2 .
- the compounds of formula (I) are prepared from a compound of the formula : wherein R 2 , R 3 , R 4 and n are as previously defined and R 6 is NH 2 or (C 1 -C 4 alkyl)S0 2 NH-, by reacting with a C 1 -C 4 alkyl sulphonylchloride or bromide, or a sulphonic anhydride of formula [(C 1 -C 4 alkyl)SO 2 ] 2 O.
- the reaction is typically carried out by stirring the reactants together in an organic solvent at room temeprature for several hours.
- a sulphonyl halide When a sulphonyl halide is used, the reaction is generally performed in pyridine but with a sulphonic anhydride, methylene chloride in a more suitable solvent.
- the product of formula (I) is isolated by removal of the solvent and purified by conventional procedures such as crystallisation or chromatography. In the case where R 6 is NH 2 , R 1 and R 5 in the product of formula (1) will naturally be the same depending on the particular reagent used.
- the starting materials of formula (III) wherein R 8 is NH 2 are prepared from readily available starting materials as shown in the following reaction scheme wherein R 2 , R 3 , R 4 and n are as previously defined and Q is a good leaving group, for example Cl, Br, I, methanesulphonyloxy, phenylsulphonyloxy or para-toluenesul- phonyloxy ; bromine being generally preferred :
- the initial reaction between the compounds offormula (IV) and (V) is typically achieved by heating the reactants in an organic solvent in the presence of an acid binding agent such as potassium carbonate.
- an acid binding agent such as potassium carbonate.
- the reaction may be achieved by refluxing the reactants in acetonitrile for a period of one or two days.
- the product (VI) is then reduced, for example by catalytic hydrogenation over palladium on charcoal to yield the amine starting material of formula (III) wherein R 8 is NH 2 .
- the process involves reacting the amine of formula (VII) with, for example, an azido-O-methanesulphonyl alkanol to yield the azide (VIII) which is reduced by catalytic hydrogenation to give the amine (IX) wherein R 3 is hydrogen.
- this product can be alkylated, for example by reaction with an alkyl halide, to give compounds of formula (IX) wherein R 3 is C 1 -C 4 alkyl.
- the reaction between the amine (IX) and the benzoyl halide (X) is typically carried out by stirring the reactants in equimolar proportions in an organic solvent, for example butan-2-one, either at room temperature or for a shorter period under reflux.
- the product (XI) is finally reduced as previously described to yield the starting material of formula (III) wherein R 8 is (C 1 -C 4 alkyl)SO 2 NH.
- salts are readily prepared by mixing solutions containing equimolar amounts of the free base and the desired acid.
- the salt generally precipitates from solution or is recovered by evaporation of the solvent.
- the biological activity of the compounds of the invention is assessed by measuring the effect of the compounds on atrial refractoriness.
- guinea pig right hemiatria are mounted in a bath containing physiological salt solution, with one end connected to a force transducer.
- the tissues are stimulated at 1 Hz using field electrodes.
- Effective refractory period (ERP) is measured by introducing premature stimuli (S2) after every 8th basic stimulus (S 1 ) '
- S l S 2 coupling interval is gradually increased until S 2 reproducibly elicits a propagated response. This is defined as the ERP.
- the test compound is then added to the bath and the concentration of compound required to increase ERP by 25% is determined (ED 25 ).
- ERP is also measured in guinea pig right papillary muscles incubated in physiological saline solution. Muscles are stimulated at one end using bipolar electrodes and the propagated electrogram is recorded at the opposite end via a unipolar surface electrode. ERP is determined as above using the extrastimulus technique. Conduction time is obtained from a digital storage oscilloscope by measuring the interval between the stimulus artefact and the peak of the electrogram (i.e. the time required for the impulse to travel along the length of the muscle).
- Atrial and vetricular ERP's are also measured in anaesthetised or conscious dogs by the extrastimulus technique whilst the atrium or right ventricle is being paced at a constant rate.
- the compounds of the formula (I) can be administered alone but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. They can be administered both to patients suffering from arrhythmias and also prophylactically to those likely to develop arrhythmias. For example they may be administered orally in the form of tablets containing such excipients as starch or lactose, or in capsules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents. They may be injected parenterally, for example, intravenously, intramuscularly or subcutaneously. For parenteral administration, they are best used in the form of a sterile aqueous solution which may contain other solutes, forexample, enough salts or glucose to make the solution isotonic with blood.
- oral dosages of the compounds of the invention will be in the range from 1 to 75 mg daily, taken in up to 4 divided doses per day, for an average adult patient (70 kg).
- individual tablets or capsules might contain 1 to 25 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier.
- Dosages for intravenous administration would be expected to be within the range 0.5 to 10 mg per single dose as required.
- a severe cardiac arrhythmia is preferably treated by the i.v. route in order to effect a rapid conversion to the normal rhythm. Variations on these dosages may occur depending on the weight and condition of the subject being treated as will be determined by the medical practitioner.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the formula (I) as defined above or pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.
- the invention also provides a method of preventing or reducing cardiac arrhythmias in a human being, which comprises administering to said human an effective amount of a compound of formula (I) or pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined above.
- the invention yet further provides a compound of the formula (I) or pharmaceutically acceptable salt thereof, for use as an anti-arrhythmia agent.
- the invention also provides the use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention or reduction of cardiac arrhythmias.
- N-2-(Methylamino)ethyl-4-nitrobenzamide (1.5 g, 6.7 mmole), 4-nitrophenethyl bromide (1.54 g, 6.7 mmole) and potassium carbonate (0.93 g, 6.7 mmole) in acetonitrile (50 ml) were stirred at reflux temperature for2 days.
- the solvent was evaporated and the residue diluted with water and extracted with methylene chloride (3 x 20 ml). The organic layer was washed twice with aqueous sodium carbonate and three times with brine, dried over sodium sulphate and evaporated.
- Methanesulphonyl chloride (0.55 ml, 7.0 mmole) was added dropwise to a stirred solution of N-[2-(N'-4-aminophenethyl-N'-methylamino)ethyl]-4-aminobenzamide (0.9 g, 3.1 mmole) in pyridine (40 ml) at 0°C and the mixture stirred at room temperature for 18 hours. The solvent was removed by evaporation and the residue suspended in sodium bicarbonate solution which was extracted with methylene chloride (3 x 20 ml).
- Methanesulphonyl chloride (5.7 g, 5 mmole) in methylene chloride solution was added dropwise over hour to a stirred solution of 2-azidoethanol (4.3 g, 50 mmole) and triethylamine (5.0 g, 50 mmole) in methylene chloride (80 ml). After 2 hours the reaction mixture was washed with water, dried over magnesium sulphate and evaporated to dryness to give the title compound as a mobile oil (7.0 g).
- N-(4-Methanesulphonamidophenethyl)-N-methylethylenediamine (0.48 g, 1.9 mmole) and 2-methoxy-4-nitrobenzoyl chloride (0.4 g, 1.9 mmole) in butan-2-one were stirred at room temeprature for 4 hours and then heated at reflux temperature for 1 hour. The solvent was removed under reduced pressure and the residue diluted with aqueous sodium bicarbonate solution and extracted with methylene chloride (3 x 30 ml).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
- This invention relates to certain N-phenethylaminoalkyl-benzamide derivatives which are anti-arrhythmia agents useful for the treatment of cardiac conditions.
- The compounds of the invention prolong the duration of the action potential in cardiac muscle and conducting tissue, and thereby increase refractoriness to premature stimuli. Thus, they are Class III anti-arrhythmic agents according to the classification of Vaughan Williams (Anti-Arrhythmic Action, E. M. Vaughan Williams, Academic Press, 1980). They are effective in atria, ventricles and conducting tissue both in vitro and in vivo and are therefore useful for the prevention and treatment of a wide variety of ventricular and supraventricular arrhythmias including atrial and ventricular fibrillation. Because they do not alter the speed at which impulses are conducted, they have less propensity than current drugs (mostly Class I) to precipitate or aggravate arrhythmias, and they also produce less neurological side effects. Some of the compounds also have positive inotropic activity and therefore are particularly beneficial in patients with impaired cardiac pump function.
-
- R2 and R3 are each independently H or Cl-C4 alkyl ;
- R4 is H or Ci-C4 alkoxy,
and n is 2, 3 or 4. - The pharmaceutically acceptable salts of the compounds of the formula (I) include acid addition salts formed from acids which form non-toxic salts such as the hydrochloride, hydrobromide, hydroiodide, sulphate or bisulphate, phosphate or hydrogen phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, benzoate, methanesulphonate, benzenesulphonate and p-toluenesulphonate salts. Some of the compounds may also form metal salts, particularly alkaline earth and alkali metal salts. Examples include the sodium and potassium salts.
- R1 and R5 are preferably both CH3, R2 is preferably CH3 or CH2CH3, R3 is preferably H, R4 is preferably H or OCH3 and n is preferably 2.
- Thus in one particular and preferred aspect, the invention provides the compound of formula (I) wherein R1 is CH3, R2 is CH3, R3 is H, R4 is methoxy attached at the 2-position of the phenyl ring and R5 is CH3, the group -NHS02R5 being attached at the 4-position of the phenyl ring, and n is 2.
-
- These compounds are valuable intermediates for the preparation of the antiarrhythmic compounds of formula (I).
-
- The reaction is typically carried out by stirring the reactants together in an organic solvent at room temeprature for several hours. When a sulphonyl halide is used, the reaction is generally performed in pyridine but with a sulphonic anhydride, methylene chloride in a more suitable solvent. The product of formula (I) is isolated by removal of the solvent and purified by conventional procedures such as crystallisation or chromatography. In the case where R6 is NH2, R1 and R5 in the product of formula (1) will naturally be the same depending on the particular reagent used.
- The starting materials of formula (III) wherein R8 is NH2 are prepared from readily available starting materials as shown in the following reaction scheme wherein R2, R3, R4 and n are as previously defined and Q is a good leaving group, for example Cl, Br, I, methanesulphonyloxy, phenylsulphonyloxy or para-toluenesul- phonyloxy ; bromine being generally preferred :
- The initial reaction between the compounds offormula (IV) and (V) is typically achieved by heating the reactants in an organic solvent in the presence of an acid binding agent such as potassium carbonate. For example the reaction may be achieved by refluxing the reactants in acetonitrile for a period of one or two days. The product (VI) is then reduced, for example by catalytic hydrogenation over palladium on charcoal to yield the amine starting material of formula (III) wherein R8 is NH2.
-
- The process involves reacting the amine of formula (VII) with, for example, an azido-O-methanesulphonyl alkanol to yield the azide (VIII) which is reduced by catalytic hydrogenation to give the amine (IX) wherein R3 is hydrogen. If desired, this product can be alkylated, for example by reaction with an alkyl halide, to give compounds of formula (IX) wherein R3 is C1-C4 alkyl.
- In the next step, the reaction between the amine (IX) and the benzoyl halide (X) is typically carried out by stirring the reactants in equimolar proportions in an organic solvent, for example butan-2-one, either at room temperature or for a shorter period under reflux. The product (XI) is finally reduced as previously described to yield the starting material of formula (III) wherein R8 is (C1-C4 alkyl)SO2NH. This route will of course be used when it is desired that R1 and R5 in the product of formula (I) should be different
- All of the above reactions are conventional and appropriate reagents and reaction conditions for their performance and procedures for isolating the desired products will be well known to those skilled in the art in accordance with literature precedents and by reference to the Examples hereto.
- Pharmaceutically acceptable salts are readily prepared by mixing solutions containing equimolar amounts of the free base and the desired acid. The salt generally precipitates from solution or is recovered by evaporation of the solvent.
- The biological activity of the compounds of the invention is assessed by measuring the effect of the compounds on atrial refractoriness. In this test guinea pig right hemiatria are mounted in a bath containing physiological salt solution, with one end connected to a force transducer. The tissues are stimulated at 1 Hz using field electrodes. Effective refractory period (ERP) is measured by introducing premature stimuli (S2) after every 8th basic stimulus (S1)' The SlS2 coupling interval is gradually increased until S2 reproducibly elicits a propagated response. This is defined as the ERP. The test compound is then added to the bath and the concentration of compound required to increase ERP by 25% is determined (ED25). ERP is also measured in guinea pig right papillary muscles incubated in physiological saline solution. Muscles are stimulated at one end using bipolar electrodes and the propagated electrogram is recorded at the opposite end via a unipolar surface electrode. ERP is determined as above using the extrastimulus technique. Conduction time is obtained from a digital storage oscilloscope by measuring the interval between the stimulus artefact and the peak of the electrogram (i.e. the time required for the impulse to travel along the length of the muscle).
- Atrial and vetricular ERP's are also measured in anaesthetised or conscious dogs by the extrastimulus technique whilst the atrium or right ventricle is being paced at a constant rate.
- For human use the compounds of the formula (I) can be administered alone but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. They can be administered both to patients suffering from arrhythmias and also prophylactically to those likely to develop arrhythmias. For example they may be administered orally in the form of tablets containing such excipients as starch or lactose, or in capsules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents. They may be injected parenterally, for example, intravenously, intramuscularly or subcutaneously. For parenteral administration, they are best used in the form of a sterile aqueous solution which may contain other solutes, forexample, enough salts or glucose to make the solution isotonic with blood.
- For administration to man in the curative or prophylactic treatment of cardiac conditions such as ventricular and supraventricular arrhythmias, including atrial and ventricular fibrillation, it is expected that oral dosages of the compounds of the invention will be in the range from 1 to 75 mg daily, taken in up to 4 divided doses per day, for an average adult patient (70 kg). Thus for a typical adult patient, individual tablets or capsules might contain 1 to 25 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier. Dosages for intravenous administration would be expected to be within the range 0.5 to 10 mg per single dose as required. A severe cardiac arrhythmia is preferably treated by the i.v. route in order to effect a rapid conversion to the normal rhythm. Variations on these dosages may occur depending on the weight and condition of the subject being treated as will be determined by the medical practitioner.
- Thus the present invention provides a pharmaceutical composition comprising a compound of the formula (I) as defined above or pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.
- The invention also provides a method of preventing or reducing cardiac arrhythmias in a human being, which comprises administering to said human an effective amount of a compound of formula (I) or pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined above.
- The invention yet further provides a compound of the formula (I) or pharmaceutically acceptable salt thereof, for use as an anti-arrhythmia agent.
- The invention also provides the use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention or reduction of cardiac arrhythmias.
- The preparation of the compounds of the invention, the intermediates of formula (II) and certain starting materials therefor are illustrated by the following Examples :
- 4-Nitrobenzoyl chloride (8.2 g, 44 mmole) was added portionwise with simultaneous dropwise addition of 48% hydrobromic acid (11 ml, 135 mmole) to a stirred solution of N-methylethylenediamine (10 g, 135 mmole) in a mixture of ethanol (70 ml) and water (10 ml), maintaining the temperature below 40°C. The mixture was heated at reflux temperature for 1 hour, cooled, and stored at 5°C overnight. The precipitate was removed by filtration and the filtrate was evaporated to dryness. The residue was taken up in water, the acidity adjusted to pH 1.5 with hydrochloric acid and the solution chilled and filtered. The filtrate was basified with sodium hydroxide solution and extracted with methylene chloride (5 x 25 ml). The organic layers were combined, dried over sodium sulphate and evaporated. The residue was recrystallised from ethyl acetate to give the title compound (2.9 g 29%). m.p. 120-121°C. Found : C,53.8 ; H,5.9; N,18.7. C10H13N3O3 requires C,53.8 ; H,5.9 ; N,18.8%.
- 4-Nitrobenzoyl chloride (8.2 g, 44 mmole), 48% hydrobromic acid (11 ml, 135 mmole) and N-ethyl ethylenediamine (11.9 g, 135 mmole) were reacted following the procedure of Example 1 to give the title compound (3.0 g, 33%). m.p. 90-92°C. Found : C,55.5 ; H,6.4 ; N,17.6. C11H15N3O3 requires : C,55.7 ; H,6.4; N,17.7%.
- N-2-(Methylamino)ethyl-4-nitrobenzamide (1.5 g, 6.7 mmole), 4-nitrophenethyl bromide (1.54 g, 6.7 mmole) and potassium carbonate (0.93 g, 6.7 mmole) in acetonitrile (50 ml) were stirred at reflux temperature for2 days. The solvent was evaporated and the residue diluted with water and extracted with methylene chloride (3 x 20 ml). The organic layer was washed twice with aqueous sodium carbonate and three times with brine, dried over sodium sulphate and evaporated. The resulting oil was purified by column chromatography on silica eluting with methylene chloride containing methanol (0% up to 2% by volume). The appropriate fractions were combined and the solvent evaporated to give the title compound (1.6 g, 64%). Found : C,58.0 ; H,5.3 ; N,14.95. C18H20N4O5 requires C,58.1 ; H,5.4 ; N,15.05%.
- N-2-(Ethylamino)ethyl-4-nitrobenzamide (2 g, 8.4 mmole), 4-nitrophenethyl bromide (1.94 g, 8.4 mmole), and potassium carbonate (1.17 g, 8.4 mmole) were heated in acetonitrile following the procedure of Example 3 to give the title compound (0.90 g). Found : C,58.75 ; H,5.90 ; N,14.3. C19H22N4O5 requires C,59.1 ; H,5.7 ; N,14.30%.
- N-[2-(N'-4-Nitrophenethyl-N'-methylamino)ethyl-4-nitrobenzamide (1.2 g, 3.2 mmole) was stirred in ethanol with 5% palladium on charcoal (0.15 g), under a hydrogen atmosphere (3.45 bar) for 4 hours. The reaction mixture was filtered and the filtrate evaporated to dryness to give an oil, which was triturated with ethyl acetate and evaporated to give the title compound as a foam, (1.0 g, 99%) which was used without further purification. Found : C,67.9; H,7.9 ; N,17.0. C18H20N4O5.0.25 (CH3CO2C2H5) requires C,68.2; H,7.8; N,16.75%.
- N-[2-(N'-4-Nitrophenethyl-N'-ethylamino)ethyl-4-nitrobenzamide (0.85 g, 2.2 mmole) was hydrogenated following the procedure of Example 5 to give the title compound (0.48 g). 1H-n.m.r. (CDCl3) δ = 7.10 (q, 4H) ; 6.90 (q, 4H) ; 3.45 (q, 4H), 2.70 (m, 8H) ; 1.05 (t, 3H).
- Methanesulphonyl chloride (0.55 ml, 7.0 mmole) was added dropwise to a stirred solution of N-[2-(N'-4-aminophenethyl-N'-methylamino)ethyl]-4-aminobenzamide (0.9 g, 3.1 mmole) in pyridine (40 ml) at 0°C and the mixture stirred at room temperature for 18 hours. The solvent was removed by evaporation and the residue suspended in sodium bicarbonate solution which was extracted with methylene chloride (3 x 20 ml). The combined organic layers were washed twice with sodium bicarbonate solution and three times with brine, dried over sodium sulphate and evaporated to give an oil which was chromatographed on silica eluting with methylene chloride containing methanol (0% up to 5% by volume). The appropriate fractions were combined and evaporated to give the title compound as a colourless foam (0.60 g 43%). Found : C,50.65 ; H,6.1 ; N,11.6. C20H28N4O5S2 H2O requires C,50.3; H,6.1 ; N,11.7%.
- N-[2-(N'-4-Aminophenethyl-N'-ethylamino)ethyl]-4-aminobenzamide (0.48 g, 1.47 mmole) was reacted with methanesulphonyl chloride (0.23 ml, 3.0 mmole) following the procedure of Example 7 to give the title compound (0.26 g). Found : C,51.9 ; H,6.4 ; H,11.4. C21H23N4O5S2 requires C,52.3 ; H,6.3 ; N,11.6%.
- Methanesulphonyl chloride (5.7 g, 5 mmole) in methylene chloride solution was added dropwise over hour to a stirred solution of 2-azidoethanol (4.3 g, 50 mmole) and triethylamine (5.0 g, 50 mmole) in methylene chloride (80 ml). After 2 hours the reaction mixture was washed with water, dried over magnesium sulphate and evaporated to dryness to give the title compound as a mobile oil (7.0 g).
- A mixture of N-(4-Methanesulphonamidophenethyl)methylamine (6.1 g, 26.8 mmole), 2-azido-O-methane sulphonyl-ethanol (4.4 g, 26.7 mmole) and sodium bicarbonate (5 g) in acetonitrile (100 ml) was heated at reflux temperature for 2.5 hours. The solvent was removed and the residue extracted with methylene chloride. The extract was filtered and the solvent evaporated. The residue was chromatographed on silica, eluting with methylene chloride containing methanol (from 0% up to 2% by volume). The appropriate fractions were combined and evaporated to give the title azide as an oil (5.4 g, 68%).
- The above product (0.9 g, 33 mmole) in ethanol (50 ml) was stirred under an atmosphere of hydrogen (3.45 bar) at room temperature for 2 hours in the presence of 5% palladium on charcoal catalyst (0.1 g). The reaction mixture was filtered and evaporated to give the title diamine as a powder (0.51 g, 62%), m.p. 90-92°C. Found: C,52.8 ; H,7.8 ; N,15.2. C12H21N3O2S requires C,53.1 ; H,7.8 ; N,15.5%.
- N-(4-Methanesulphonamidophenethyl)-N-methylethylenediamine (0.48 g, 1.9 mmole) and 2-methoxy-4-nitrobenzoyl chloride (0.4 g, 1.9 mmole) in butan-2-one were stirred at room temeprature for 4 hours and then heated at reflux temperature for 1 hour. The solvent was removed under reduced pressure and the residue diluted with aqueous sodium bicarbonate solution and extracted with methylene chloride (3 x 30 ml). The combined organic layers were washed three times with brine, dried over sodium sulphate and evaporated to an oil which was chromatographed on silica eluting with methylene chloride containing methanol (0% up to 2% by volume). The appropriate fractions were combined and evaporated to give the title compound as a foam, (0.51 g, 64%). Found : C,52.0 ; H,5.8 ; N,11.8. C20H28N4O8S.H20 requires C,52.3 ; H,5.9 ; H,12.2%.
- N-[2-(N'-4-Methanesulphonamidophenethyl-N'-methylamino)ethyl]-2-methoxy-4-nitrobenzamide (0.5 g, 1.19 mmole) was converted to the title compound by catalytic hydrogenation following the procedure of Example 5. Yield 0.45 g. 1H-n.m.r. (CDCI3) δ = 8.00 (d, 1H) ; 7.15 (q, 4H) ; 6.35 (q, 1H) ; 6.25 (d, 1H) ; 4.00 (s, 2H) ; 3.85 (s, 3H) ; 3.50 (q, 2H) ; 2.95 (s, 3H) ; 2.75 (d, 2H) ; 2.70 (d, 2H) ; 2.65 (q, 2H) ; 2.40 (s, 3H).
- N-[2-(N'-4-Methanesulphonamidophenethyl-N'-methylamino)ethyl]-4-amino-2-methoxybenzamide (0.44 g, 1.0 mmole) was reacted with methanesulphonyl chloride (0.081 ml, 1.0 mmole) following the procedure of Example 7 to yield the title product (0.23 g, 47%). Found : C,50.5 ; H,6.05 ; N,11.0. C21H30N4O6S2 requires C,50.8; H,6.1 ; N,11.2%.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT88302270T ATE63541T1 (en) | 1987-03-20 | 1988-03-16 | N-PHENYLETHYLAMINOALKYL BENZAMIDES AS ANTIARHYTHMIC AGENTS. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8706662 | 1987-03-20 | ||
GB878706662A GB8706662D0 (en) | 1987-03-20 | 1987-03-20 | Anti-arrhythmia agents |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0285284A2 EP0285284A2 (en) | 1988-10-05 |
EP0285284A3 EP0285284A3 (en) | 1989-03-29 |
EP0285284B1 true EP0285284B1 (en) | 1991-05-15 |
Family
ID=10614327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP88302270A Expired - Lifetime EP0285284B1 (en) | 1987-03-20 | 1988-03-16 | N-phenethylaminoalkyl-benzamide anti-arrhythmia agents |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0285284B1 (en) |
JP (1) | JPS63255258A (en) |
AT (1) | ATE63541T1 (en) |
DE (1) | DE3862791D1 (en) |
DK (1) | DK148288A (en) |
ES (1) | ES2035915T3 (en) |
GB (1) | GB8706662D0 (en) |
GR (1) | GR3001955T3 (en) |
PT (1) | PT87005B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4906634A (en) * | 1988-03-08 | 1990-03-06 | Schering A.G. | Novel N-[4-(aminosubstituted)phenyl]methanesulfonamides and their use as cardiovascular agents |
US5215989A (en) * | 1989-12-08 | 1993-06-01 | Merck & Co., Inc. | Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents |
US5032604A (en) * | 1989-12-08 | 1991-07-16 | Merck & Co., Inc. | Class III antiarrhythmic agents |
US5112824A (en) * | 1989-12-08 | 1992-05-12 | Merck & Co., Inc. | Benzofuran compounds as class III antiarrhythmic agents |
US5032598A (en) * | 1989-12-08 | 1991-07-16 | Merck & Co., Inc. | Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents |
US5382587A (en) * | 1993-06-30 | 1995-01-17 | Merck & Co., Inc. | Spirocycles |
US5403846A (en) * | 1993-11-22 | 1995-04-04 | Merck & Co., Inc. | Spirocycles |
US5439914A (en) * | 1994-02-18 | 1995-08-08 | Merck & Co., Inc. | Spirocycles |
FR2726267B1 (en) * | 1994-10-26 | 1998-01-02 | Smithkline Beecham Lab | NOVEL ARRHYTHMIC AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR PREPARING THEM |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4544654A (en) * | 1984-03-20 | 1985-10-01 | Schering A.G. | Substituted sulfonamidobenzamides, antiarrhythmic agents and compositions thereof |
EP0164865B1 (en) * | 1984-05-04 | 1988-12-21 | The Upjohn Company | N-(aminoalkylphenyl)sulfonamides their preparation and therapeutic use |
CA1241967A (en) * | 1984-05-11 | 1988-09-13 | George C. Buzby Jr. | Sulfonamides useful as anti-arrhythmic agents |
US4569801A (en) * | 1984-10-15 | 1986-02-11 | Eli Lilly And Company | Alkylsulfonamidophenylalkylamines |
-
1987
- 1987-03-20 GB GB878706662A patent/GB8706662D0/en active Pending
-
1988
- 1988-03-16 EP EP88302270A patent/EP0285284B1/en not_active Expired - Lifetime
- 1988-03-16 ES ES198888302270T patent/ES2035915T3/en not_active Expired - Lifetime
- 1988-03-16 AT AT88302270T patent/ATE63541T1/en not_active IP Right Cessation
- 1988-03-16 DE DE8888302270T patent/DE3862791D1/en not_active Expired - Lifetime
- 1988-03-18 PT PT87005A patent/PT87005B/en not_active IP Right Cessation
- 1988-03-18 DK DK148288A patent/DK148288A/en not_active Application Discontinuation
- 1988-03-22 JP JP63068006A patent/JPS63255258A/en active Pending
-
1991
- 1991-05-16 GR GR91400580T patent/GR3001955T3/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP0285284A3 (en) | 1989-03-29 |
JPS63255258A (en) | 1988-10-21 |
ATE63541T1 (en) | 1991-06-15 |
GR3001955T3 (en) | 1992-11-23 |
ES2035915T3 (en) | 1993-05-01 |
GB8706662D0 (en) | 1987-04-23 |
DE3862791D1 (en) | 1991-06-20 |
PT87005B (en) | 1992-06-30 |
EP0285284A2 (en) | 1988-10-05 |
DK148288D0 (en) | 1988-03-18 |
PT87005A (en) | 1988-04-01 |
DK148288A (en) | 1988-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4788196A (en) | Phenyl piperazine anti-arrhythmia agents | |
EP0281254B1 (en) | Antiarrythmic agents | |
EP0286278B1 (en) | Indanamine derivatives useful as antiarrhythmic agents | |
US5057528A (en) | Amino-pyridine compounds useful as anti-arrhythmic agents | |
EP0257864B1 (en) | Antiarrhythmic agents | |
EP0285284B1 (en) | N-phenethylaminoalkyl-benzamide anti-arrhythmia agents | |
EP0307121B1 (en) | Sulphonamide antiarrhythmic agents | |
EP0284384B1 (en) | Anti-arrhythmic agents | |
EP0291210B1 (en) | Antiarrhythmic agents | |
US5130334A (en) | Indane sulfonamide anti-arrhythmic agents | |
EP0285323B1 (en) | Antiarrhythmic agents | |
EP0324543A2 (en) | Antiarrhythmic agents | |
WO1992006080A1 (en) | Antiarrhythmic agents | |
IL86459A (en) | Indane sulfonamides, their preparation, pharmaceutical compositions containing them and intermediates therefor | |
PT86702B (en) | PROCESS FOR PREPAPPING METHANE-SULFONAMIDE-REPLACED PHENETHYLAMINES | |
HU201002B (en) | Process for production of derivatives of indan sulphamid and medical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19880321 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19900802 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 19910515 |
|
REF | Corresponds to: |
Ref document number: 63541 Country of ref document: AT Date of ref document: 19910615 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 3862791 Country of ref document: DE Date of ref document: 19910620 |
|
ET | Fr: translation filed | ||
ITF | It: translation for a ep patent filed |
Owner name: MODIANO & ASSOCIATI S.R.L. |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 19911211 Year of fee payment: 5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Effective date: 19920316 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19920317 Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19920317 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Effective date: 19920331 Ref country code: CH Effective date: 19920331 Ref country code: BE Effective date: 19920331 |
|
EPTA | Lu: last paid annual fee | ||
26N | No opposition filed | ||
BERE | Be: lapsed |
Owner name: PFIZER LTD Effective date: 19920331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19921001 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Effective date: 19921130 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19921201 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19930316 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2035915 Country of ref document: ES Kind code of ref document: T3 |
|
EUG | Se: european patent has lapsed |
Ref document number: 88302270.9 Effective date: 19921005 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: MH4A Free format text: 3001955 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 19990405 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20030204 Year of fee payment: 16 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040316 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20040316 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20050316 |